Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Walter Fried"'
Autor:
Robert B. Epstein, Walter Fried
Publikováno v:
Postgraduate medicine. 55(5)
Autor:
Walter Fried
Publikováno v:
Experimental Hematology. 37:1007-1015
Although the concept of a humoral regulator of erythropoiesis was introduced more than 100 years ago, its existence was first firmly established a little more than 50 years ago. This review briefly describes the historical development of information
Publikováno v:
Annals of the New York Academy of Sciences. 77:551-573
Publikováno v:
Oncology (Williston Park, N.Y.). 27(2)
Diffuse large B-cell non-Hodgkin lymphoma (DLBCL) is a disease of the elderly, but our current guidelines and treatment paradigms for this disease are based on studies that have mainly enrolled younger patients. Because the number of people living be
Autor:
Walter Fried
Publikováno v:
Annual Review of Nutrition. 15:353-377
Autor:
Kathy Tolzien, Angel G. Galvez, Wendy M. Dewey, Chadi Nabhan, Walter Fried, Nancy Davis, Susan Foss, Jacob D. Bitran, Parameswaran Venugopal
Publikováno v:
Cancer. 117(7)
BACKGROUND: Currently, no standard therapy exists for patients with relapsed and/or refractory non-Hodgkin lymphoma (NHL) who are ineligible for transplantation or who have failed after bone marrow transplantation. The authors of this report investig
Publikováno v:
Journal of the American Academy of Dermatology. 28(5 Pt 1)
Autor:
Laura Magid, Angel G. Galvez, Jacob D. Bitran, Walter Fried, Kathy Tolzien, Wendy M. Dewey, Parameswaran Venugopal, Chadi Nabhan
Publikováno v:
Blood. 114:921-921
Abstract 921 Background: CLO is a second generation nucleoside analogue with known activity in acute leukemia and myelodysplasia. As there is no standard therapy for refractory and transplant-ineligible relapsed NHL, and given the activity that purin
Autor:
Jacob D. Bitran, Walter Fried, Chadi Nabhan, Phillip Gozun, Parameswaran Venugopal, Angel G. Galvez
Publikováno v:
Blood. 110:4462-4462
There is no known standard of care for pts with relapsed and/or refractory NHL who cannot undergo stem cell transplantation (SCT) or have relapsed after SCT. Such pts are candidates for new therapies. CLO is a novel nucleoside analogue with known act
Autor:
Richard M. Freeman, Walter Fried, Richard L. DeGowin, Thomas P. Gibson, William W. Bonney, Kenneth K. Wu
Publikováno v:
Archives of Internal Medicine. 132:898-902
Since anemia is one of the main obstacles to optimal rehabilitation of anephric patients supported with hemodialysis, it is ironic that erythrocytosis has proved a troublesome complication in a few patients who have undergone renal transplantation. T